Targeted agents and immunotherapies: optimizing outcomes in melanoma
Abstract Treatment options for patients with metastatic melanoma, and especially BRAF-
mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of …
mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of …
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines
SM Swetter, JA Thompson, MR Albertini… - Journal of the National …, 2021 - jnccn.org
Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been
expanded to include pathways for treatment of microscopic satellitosis (added in v2. 2020) …
expanded to include pathways for treatment of microscopic satellitosis (added in v2. 2020) …
Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology
DG Coit, JA Thompson, MR Albertini, C Barker… - Journal of the National …, 2019 - jnccn.org
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous
melanoma have been significantly revised over the past few years in response to emerging …
melanoma have been significantly revised over the past few years in response to emerging …
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Background The combination of cobimetinib with vemurafenib improves progression-free
survival compared with placebo and vemurafenib in previously untreated patients with BRAF …
survival compared with placebo and vemurafenib in previously untreated patients with BRAF …
[HTML][HTML] European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment–update 2019
C Garbe, T Amaral, K Peris, A Hauschild… - European Journal of …, 2020 - Elsevier
A unique collaboration of multidisciplinary experts from the European Dermatology Forum,
the European Association of Dermato-Oncology and the European Organization for …
the European Association of Dermato-Oncology and the European Organization for …
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Background Previously, a study of ours showed that the combination of dabrafenib and
trametinib improves progression-free survival compared with dabrafenib and placebo in …
trametinib improves progression-free survival compared with dabrafenib and placebo in …
[HTML][HTML] Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
Background The combined inhibition of BRAF and MEK is hypothesized to improve clinical
outcomes in patients with melanoma by preventing or delaying the onset of resistance …
outcomes in patients with melanoma by preventing or delaying the onset of resistance …
Melanoma
D Schadendorf, DE Fisher, C Garbe… - Nature reviews Disease …, 2015 - nature.com
Melanoma is a common cancer in the Western world with an increasing incidence. Sun
exposure is still considered to be the major risk factor for melanoma. The prognosis of …
exposure is still considered to be the major risk factor for melanoma. The prognosis of …
[HTML][HTML] Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: current status in clinical trials
Y Song, Z Bi, Y Liu, F Qin, Y Wei, X Wei - Genes & diseases, 2023 - Elsevier
Molecular target inhibitors have been regularly approved by Food and Drug Administration
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …